EU and US could reach trade deal this weekend - Reuters
On Wednesday, Piper Sandler maintained a positive outlook on Align Technology shares (NASDAQ:ALGN), reaffirming an Overweight rating and a $235.00 price target. The firm’s analyst highlighted a mixed performance for the company in the first quarter, noting a decline in March clear aligner volumes by 1.7% year-over-year. This decrease contributed to an overall drop of 6.0% for the quarter, with a slightly higher 6.4% decline reported for the teen demographic. According to InvestingPro data, the company maintains strong fundamentals with a 70% gross profit margin and healthy financial metrics, despite recent headwinds.
The analyst acknowledged that while the full quarter’s performance was not particularly strong, it ended on a better note than it started. As a result, Piper Sandler has adjusted its first-quarter estimates for Align Technology downward, although the firm expects less impact on full-year estimates due to potential offsets from foreign exchange movements. InvestingPro analysis shows the company appears undervalued at current levels, with analysts projecting EPS of $10.06 for FY2025.
Despite the recent challenges, the analyst expressed belief in the stock’s potential, suggesting that current market valuations have already factored in concerns over consumer sentiment and recessionary fears, as well as mixed industry data. With a solid Altman Z-Score of 4.87 and minimal debt-to-equity ratio of 0.03, InvestingPro data indicates strong financial health. Align Technology’s stock has attracted investor attention, particularly as the company approaches its Investor Day on May 6, which is anticipated to provide insights into long-range plans, product pipeline, and progress in direct fabrication.
Piper Sandler’s stance remains firm on purchasing the stock, with the belief that the potential downsides and associated risks are already reflected in the price. The reiterated Overweight rating and price target of $235 indicate continued confidence in Align Technology’s prospects. With management actively buying back shares and maintaining profitability, InvestingPro subscribers can access detailed analysis and additional insights through the comprehensive Pro Research Report, available for over 1,400 US stocks.
In other recent news, Align Technology has been the focus of several analyst updates and product developments. Stifel analysts have maintained their Buy rating for Align Technology with a price target of $275, citing potential for the company’s first-quarter results to exceed expectations. They also noted a stabilization in market share for the Invisalign product, particularly in China. Mizuho (NYSE:MFG) Securities, on the other hand, has adjusted its price target for Align Technology to $250 while maintaining an Outperform rating. This adjustment was influenced by competitor Angelalign’s performance and market conditions, including tariff impacts.
In a separate development, Align Technology announced the release of a new Invisalign product designed for younger patients with Class II malocclusions. This product includes occlusal blocks aimed at improving treatment outcomes. The new system is expected to be available to Invisalign-trained doctors in several regions, with broader availability anticipated in 2025. Meanwhile, the global tariff environment has been a point of focus, with Mizuho highlighting potential impacts on Align’s operations, particularly concerning exemptions for USMCA-compliant goods and new tariffs on products manufactured in Israel.
Despite these challenges, Align Technology continues to receive analyst support, with Mizuho and Stifel both expressing confidence in the company’s ability to navigate current market conditions. The recent product launch and analyst insights reflect ongoing developments and strategic adjustments within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.